# A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

> **NCT02965040** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 34 (actual)

## Conditions studied

- Normal Renal Function
- Impaired Renal Function

## Interventions

- **DRUG:** Roxadustat

## Key facts

- **NCT ID:** NCT02965040
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-12
- **Primary completion:** 2017-12-04
- **Final completion:** 2017-12-11
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02965040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02965040, "A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02965040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*